Relmada Therapeutics, Inc. products

Novel MOA: REL-1017 works as an NMDAR channel blocker with preferential activity at hyperactive GluN1-GluN2D channels. REL-1017 is a novel N-methyl-D-aspartate receptor (NMDAR) channel blocker in phase 3 clinical trials for the treatment of Major Depressive Disorder (MDD). REL-1017 works with a MOA markedly different from standard serotoninergic antidepressants.